Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
RO5313534 · 2 trials · 2 indications
| Arm | Type | Description |
|---|---|---|
| Placebo | PLACEBO_COMPARATOR | - |
| RO5313534 15mg | EXPERIMENTAL | - |
| RO5313534 1mg | EXPERIMENTAL | - |
| RO5313534 5mg | EXPERIMENTAL | - |
| Single Arm | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| Placebo | DRUG | po daily for 24 weeks |
| RO5313534 | DRUG | 1mg po daily for 24 weeks |
| memantine | DRUG | multiple doses to steady state |
Inclusion Criteria: * adult patients, \>/=50 years of age; * probable Alzheimer's disease; * MMSE score at screening of 13-22; * under stable donepezil treatment given at a fixed dose of 5 or 10mg daily for \>=4 months prior to baseline; * not requiring nursing home care, but looked after by a care...
Top 20 of 24 competitors
RO5313534 is an investigational small molecule being studied as an add-on to donepezil treatment in patients with mild to moderate Alzheimer's Disease. It is developed by Roche Holding AG (RHHBY). The drug is in Phase 2 clinical development for this indication, though no efficacy results have been reported.
The molecular target of RO5313534 has not been disclosed in available information. It is a small molecule being investigated for its potential role in treating Alzheimer's Disease, but its specific mechanism of action is not publicly detailed.
RO5313534 is being developed by Roche Holding AG, which trades under the ticker RHHBY. The company is conducting clinical trials to evaluate the drug's safety and efficacy in Alzheimer's Disease and healthy volunteers.
RO5313534 is in Phase 2 clinical development for Alzheimer's Disease. It has completed one Phase 2 trial and one Phase 1 trial. The drug is investigational and has not been approved by regulatory authorities.
RO5313534 has been studied in two completed trials. NCT00884507 was a Phase 2 study of RO5313534 as add-on to donepezil in mild to moderate Alzheimer's Disease with 389 participants. NCT01196065 was a Phase 1 study in healthy volunteers evaluating drug interactions with memantine, enrolling 16 participants.
RO5313534 is not known to have alternative names. It is identified solely by its code name RO5313534 in clinical trial registries and available information.